Ajanta Pharma Limited (NSE: AJANTPHARM, BSE: 532331) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹41,591 Cr, it ranks #228 by market cap among the 6,137 Indian listed companies on FinBizNet, and #2 of 63 in Pharmaceuticals. At ₹3,283.90 (as of 25 Oct 2026), the share price is 13.5% below its 52-week high of ₹3,796.00 and 37.9% above its 52-week low of ₹2,382.00. The share price is up 36.3% over one year and down 2.5% over three months.
| Current Price | ₹3,283.90 |
|---|---|
| Market Cap | ₹41,591 Cr |
| NSE Symbol | AJANTPHARM |
| BSE Code | 532331 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 39 |
| Return on Equity | 25.39% |
| Return on Assets | 14.85% |
| 52-Week Range | ₹2,382.00 – ₹3,796.00 |
| 1-Year Price Change | +36.3% |
| 3-Month Price Change | -2.5% |
| Beta (1Y) | 0.11 |
| Dividend Yield | 1.94% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.ajantapharma.com |
| Revenue | ₹1,626 Cr |
|---|---|
| Net Profit | ₹334 Cr |
| Net Margin | 20.6% |
| EPS (Basic) | ₹26.75 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.
1. Pharmaceuticals-This segment offers pharmaceutical and related products. 2. Pharmaceuticals-This segment offers pharmaceuticals and related products.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Astrazeneca Pharma India Ltd. | ₹14,915 Cr | 80.6 | 22.82% | ₹683 Cr | -34.5% |
Listed by market capitalisation. Ratios are shown for context only.
Ajanta Pharma Limited is trading at ₹3,283.90, with a market capitalisation of ₹41,591 Cr.
Ajanta Pharma Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Ajanta Pharma Limited has a P/E of 39 and a return on equity of 25.39%.
Ajanta Pharma Limited is listed on the NSE under the symbol AJANTPHARM and on the BSE under the scrip code 532331.
Ajanta Pharma Limited's share price is up 36.3% over one year and down 2.5% over three months. Its 52-week range is ₹2,382.00 to ₹3,796.00.
In Q1 FY27, Ajanta Pharma Limited reported revenue of ₹1,626 Cr and net profit of ₹334 Cr, with basic EPS of ₹26.75 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.